Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019;4:545–58.

Article  PubMed  PubMed Central  Google Scholar 

Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B. Infect Dis Info. 2023,36:1–17.

Deng W, Jiang TT, Bi XY, et al. Progress on the treatment of chronic hepatitis B with interferons. Chin J liver disea. 2023;15:1–6.

Google Scholar 

China Center for Disease Control and Prevention. Summary of epidemic situation of Class A, B and C infectious diseases in China in March 2022. Dis detect. 2022;37:421.

Google Scholar 

Wang GQ, Liang P, Li P, Tan YH, Bonkovsky HL. The role of traditional Chinese medicines (TCM) and other complementary and alternative medicines (CAM) in the management of chronic hepatitis B. Curr Hepatol Rep. 2019;18:316–21.

Article  Google Scholar 

Seo JW, Kim K, Jun KI, Kang CK, Moon SM, Song KH, et al. Recovery of tenofovir-induced nephrotoxicity following switch from tenofovir disoproxil fumarate to tenofovir alafenamide in human immunodeficiency virus-positive patients. Infect Chemother. 2020;52:381–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hepatobiliary disease Committee of Chinese Association of Traditional Chinese Medicine, hepatopathy Committee of Chinese Association of Ethnic Medicine. TCM diagnosis and treatment guide for chronic hepatitis B. Chin J Int Trad West Med Liver Dis. 2019;29:97–102.

Google Scholar 

Liu Y, Yao W, Si L, Hou J, Wang J, Xu Z, et al. Chinese herbal extract Su-duxing had potent inhibitory effects on both wild-type and entecavir-resistant hepatitis B virus (HBV) in vitro and effectively suppressed HBV replication in mouse model. Antiviral Res. 2018;155:39–47.

Article  CAS  PubMed  Google Scholar 

Sang XX, Wang RL, Han YZ, Zhang CE, Shen HH, Yang ZR, et al. T cell–associated immunoregulation and antiviral effect of oxymatrine in hydrodynamic injection HBV mouse model. Acta Pharmaceutica Sinica B. 2017;7:311–8.

Article  PubMed  PubMed Central  Google Scholar 

Wei L, Ploss A. Hepatitis B virus cccDNA is formed through distinct repair processes of each strand. Nat Commun. 2021;12:1591.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lythgoe KA, Lumley SF, Pellis L, Matthews PC. Estimating hepatitis B virus cccDNA persistence in chronic infection. Virus Evol. 2021;7: veaa063.

Article  PubMed  Google Scholar 

Hsu YC, Jun DW, Peng CY, Yeh ML, Trinh HN, Wong GLH, et al. Entecavir versus tenofovir disoproxil fumarate for seroclearance of hepatitis B surface antigen in an international real-world cohort. Hepatology. 2021;74:714.

Google Scholar 

Li YW, Yang FC, Lu HQ, Zhang JS. Hepatocellular carcinoma and hepatitis B surface protein. World J Gastroenterol. 2016;22:1943–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xie P, Zhang X. Research progress on hepatitis B virus surface antigen. Chin J Viral Dis. 2020;10:333–6.

Google Scholar 

Tout I, Loureiro D, Mansouri A, Soumelis V, Boyer N, Asselah T. Hepatitis B surface antigen seroclearance: immune mechanisms, clinical impact, importance for drug development. J Hepatol. 2020;73:409–22.

Article  CAS  PubMed  Google Scholar 

Zannetti C, Roblot G, Charrier E, Ainouze M, Tout I, Briat F, et al. Characterization of the inflammasome in human Kupffer cells in response to synthetic agonists and pathogens. J Immunol. 2016;197:356–67.

Article  CAS  PubMed  Google Scholar 

Boltjes A, Montfoort N, Biesta PJ, Brouw ML, Kwekkeboom J, Laan LJ, et al. Kupffer cells interact with hepatitis B surface antigen in vivo and in vitro, leading to proin-flammatory cytokine production and natural killer cell function. J Infect Dis. 2015;211:1268–78.

Article  CAS  PubMed  Google Scholar 

Molen RG, Sprengers D, Binda RS, Jong EC, Niesters HG, Kusters JG, et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology. 2004;40:738–46.

Article  PubMed  Google Scholar 

Brouw ML, Binda RS, Roosmalen MH, Protzer U, Janssen HL, Molen RG, et al. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology. 2009;126:280–9.

Article  Google Scholar 

Woltman AM, Brouw ML, Biesta PJ, Shi CC, Janssen HL. Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS ONE. 2011;6: e15324.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu YF, Hu YW, Shi BS, Zhang XN, Wang JF, Zhang ZQ, et al. HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol Immunol. 2009;46:2640–6.

Article  CAS  PubMed  Google Scholar 

Kondo Y, Shimosegawa T. Significant roles of regulatory T cells and myeloid derived suppressor cells in hepatitis B virus persistent infection and hepatitis B virus-related HCCs. Int J Mol Sci. 2015;16:3307–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alexopoulou A, Vasilieva L, Karayiannis P. New approaches to the treatment of chronic hepatitis B. J Clin Med. 2020;9:3187.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ye B, Liu X, Li X, Kong H, Tian L, Chen Y. T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death Dis. 2015;6(3):1694.

Article  Google Scholar 

Dong Y, Li X, Zhang L, Zhu Q, Chen C, Bao J, et al. CD4+ T cell exhaustion revealed by high PD-1 and LAG-3 expression and the loss of helper T cell function in chronic hepatitis B. BMC Immunol. 2019;20:27.

Article  PubMed  PubMed Central  Google Scholar 

Tout I, Gomes M, Ainouze M, Marotel M, Pecoul T, Durantel D, et al. Hepatitis B virus blocks the CRE/CREB complex and prevents TLR9 transcription and function in human B cells. J Immunol. 2018;201:2331–44.

Article  CAS  PubMed  Google Scholar 

Li YH, Ge FL, Chen R, Bai ZF, Li L, Zhao J, et al. Research progress on nucleos(t)ide analogues resistance mechanism and mutation sites. Chin J Pharm. 2021;18:795–9.

Google Scholar 

Liu Y, Miller MD, Rinos KM. HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D. Liver Int. 2014;34:1025–32.

Article  CAS  PubMed  Google Scholar 

Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology. 2006;44:703–12.

Article  CAS  PubMed  Google Scholar 

Liu Y, Chen RJ, Liu WH, Si LL, Li L, Li XD, et al. Investigation of multidrug-resistance mutations of hepatitis B virus (HBV) in a large cohort of chronic HBV-infected patients with treatment of nucleoside/nucleotide analogs. Antiviral Res. 2021;189: 105058.

Article  CAS  PubMed  Google Scholar 

Chen RJ, Liu Y, Luo D, Si LL, Huang BX, Wang J, et al. Hepatitis B virus mutation pattern rtA181S+T184I+M204I may contribute to multidrug resistance in clinical practice: analysis of a large cohort of Chinese patients. Antiviral Res. 2020;180: 104852.

Article  CAS  PubMed  Google Scholar 

Lim YS, Byun KS, Yoo BC, Kwon SY, Kim YJ, An J, et al. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. Gut. 2016;65:852–60.

Article  CAS  PubMed  Google Scholar 

Suzuki F, Suzuki Y, Hosaka T, Sezaki H, Akuta N, Fujiyama S, et al. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs. J Gastroenterol. 2017;52:641–51.

Article  CAS  PubMed  Google Scholar 

Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68:672–81.

Article  CAS  PubMed  Google Scholar 

Park ES, Lee AR, Kim DH, Lee JH, Yoo JJ, Ahn SH, et al. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. J Hepatol. 2019;70:1093–102.

Article  CAS  PubMed  Google Scholar 

Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137:1593–608.

Article  CAS  PubMed  Google Scholar 

Zhou P, Qu SY. Research status of nucleoside (acid) analogues in the treatment of viral resistance sites in patients with chronic hepatitis B. Chin J Inte Trad West Med Liver Disea. 2020;30:188–92.

Google Scholar 

Antonio B, Tan AT, Gehring AJ. HBV-specific adaptive immunity. Viruses. 2009;1:91–103.

Article  Google Scholar 

Yang PW, Zhao WX. Research status of TCM intervention in hepatitis B virus resistance. TCM Clin Res. 2014;6:144–5.

Google Scholar 

Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98.

Article  CAS  PubMed  Google Scholar 

Lu FM, Feng B, Zheng SJ, Jiang SZ, Yang RF, Fu JL, et al. Current status of the research on low level viremia in chronic hepatitis B patients receiving nucleos(t) ide analogues. J Clin Hepatol. 2021;37:1268–74.

CAS